Swellable Ciprofloxacin-Loaded Nano-in-Micro Hydrogel Particles for Local Lung Drug Delivery

Ageing International

Volumn 15, Issue 6, 2014, Pages 1535-1544

  Du, Ju ^a   El Sherbiny, Ibrahim M ^b,c   Smyth, Hugh D ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b MANSOURA UNIVERSITY   (Egypt)

^c 6th of October City   (Egypt)

Author keywords

alveolar macrophage; antibiotics; cross linking; hydrogel swelling; intratracheal insufflation

Indexed keywords

ALGINIC ACID; ANTIINFECTIVE AGENT; CHITOSAN; CIPROFLOXACIN; DELAYED RELEASE FORMULATION; DRUG CARRIER; GLUCURONIC ACID; HEXURONIC ACID; HYDROGEL; MACROGOL DERIVATIVE; NANOPARTICLE; POLYMER;

ANALOGS AND DERIVATIVES; ANIMAL; BLOOD; BRONCHOALVEOLAR LAVAGE FLUID; CELL LINE; CHEMISTRY; DELAYED RELEASE FORMULATION; DRUG EFFECTS; HYDROGEL; INHALATIONAL DRUG ADMINISTRATION; LUNG; MACROPHAGE; MALE; MEDICINAL CHEMISTRY; METABOLISM; MOUSE; NANOMEDICINE; PARTICLE SIZE; PHARMACEUTICS; PROCEDURES; SOLUBILITY; SPRAGUE DAWLEY RAT; SURFACE PROPERTY;

ADMINISTRATION, INHALATION; ALGINATES; ANIMALS; ANTI-BACTERIAL AGENTS; BRONCHOALVEOLAR LAVAGE FLUID; CELL LINE; CHEMISTRY, PHARMACEUTICAL; CHITOSAN; CIPROFLOXACIN; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; GLUCURONIC ACID; HEXURONIC ACIDS; HYDROGELS; LUNG; MACROPHAGES; MALE; MICE; NANOMEDICINE; NANOPARTICLES; PARTICLE SIZE; POLYETHYLENE GLYCOLS; POLYMERS; RATS, SPRAGUE-DAWLEY; SOLUBILITY; SURFACE PROPERTIES; TECHNOLOGY, PHARMACEUTICAL;

EID: 84912059520     PISSN: 01635158     EISSN: 1936606X     Source Type: Journal    
DOI: 10.1208/s12249-014-0176-x     Document Type: Article

References (42)

1. Geller DE. Aerosol antibiotics in cystic fibrosis. Respir Care. 2009;54:658–70.
2. Pilcer G, Sebti T, Amighi K. Formulation and characterization of lipid-coated tobramycin particles for dry powder inhalation. Pharm Res. 2006;23:931–40.
3. Weers JG, Bell J, Chan HK, Cipolla D, Dunbar C, Hickey AJ, et al. Pulmonary formulations: what remains to be done? J Aerosol Med Pulm Drug Deliv. 2010;23:S5–23.
4. Yang Y, Tsifansky MD, Wu CJ, Yang HI, Schmidt G, Yeo Y. Inhalable antibiotic delivery using a dry powder co-delivering recombinant deoxyribonuclease and ciprofloxacin for treatment of cystic fibrosis. Pharm Res. 2010;27:151–60.
5. Stass H, Weimann B, Nagelschmitz J, Rolinck-Werninghaus C, Staab D. Tolerability and pharmacokinetic properties of ciprofloxacin dry powder for inhalation in patients with cystic fibrosis: a phase I, randomized, dose-escalation study. Clin Ther. 2013;35:1571–81.
6. Ruge CA, Kirch J, Lehr CM. Pulmonary drug delivery: from generating aerosols to overcoming biological barriers—therapeutic possibilities and technological challenges. Lancet Respir Med. 2013;1:402–13.
7. Bailey MM, Berkland CJ. Nanoparticle formulations in pulmonary drug delivery. Med Res Rev. 2009;29:196–212.
8. Houtmeyers E, Gosselink R, Gayan-Ramirez G, Decramer M. Regulation of mucociliary clearance in health and disease. Eur Respir J. 1999;13:1177–88.
9. El-Sherbiny IM, McGill S, Smyth HD. Swellable microparticles as carriers for sustained pulmonary drug delivery. J Pharm Sci. 2010;99:2343–56.
10. Wanakule P, Liu GW, Fleury AT, Roy K. Nano-inside-micro: disease-responsive microgels with encapsulated nanoparticles for intracellular drug delivery to the deep lung. J Control Release. 2012;162:429–37.
11. Du J, Du P, Smyth HD. Hydrogels for controlled pulmonary delivery. Ther Deliv. 2013;4:1293–305.
12. Dellamary LA, Tarara TE, Smith DJ, Woelk CH, Adractas A, Costello ML, et al. Hollow porous particles in metered dose inhalers. Pharm Res. 2000;17:168–74.
13. Mansour HM, Rhee YS, Wu X. Nanomedicine in pulmonary delivery. Int J Nanomedicine. 2009;4:299–319.
14. Rytting E, Nguyen J, Wang X, Kissel T. Biodegradable polymeric nanocarriers for pulmonary drug delivery. Expert Opin Drug Deliv. 2008;5:629–39.
15. El-Sherbiny IM, Smyth HD. Biodegradable nano-micro carrier systems for sustained pulmonary drug delivery: (I) self-assembled nanoparticles encapsulated in respirable/swellable semi-IPN microspheres. Int J Pharm. 2010;395:132–41.
16. Byron PR. Prediction of drug residence times in regions of the human respiratory tract following aerosol inhalation. J Pharm Sci. 1986;75:433–8.
17. Patton JS, Byron PR. Inhaling medicines: delivering drugs to the body through the lungs. Nat Rev Drug Discov. 2007;6:67–74.
18. Tsapis N, Bennett D, Jackson B, Weitz DA, Edwards DA. Trojan particles: large porous carriers of nanoparticles for drug delivery. Proc Natl Acad Sci U S A. 2002;99:12001–5.
19. Selvam P, El-Sherbiny IM, Smyth HD. Swellable hydrogel particles for controlled release pulmonary administration using propellant-driven metered dose inhalers. J Aerosol Med Pulm Drug Deliv. 2011;24:25–34.
20. El-Sherbiny IM, Smyth HD. Poly (ethylene glycol)–carboxymethyl chitosan-based pH-responsive hydrogels: photo-induced synthesis, characterization, swelling, and in vitro evaluation as potential drug carriers. Carbohydr Res. 2010;345:2004–12.
21. El-Sherbiny IM, Smyth HD. Controlled release pulmonary administration of curcumin using swellable biocompatible microparticles. Mol Pharm. 2011;9:269–80.
22. Kim DH, Martin DC. Sustained release of dexamethasone from hydrophilic matrices using PLGA nanoparticles for neural drug delivery. Biomaterials. 2006;27:3031–7.
23. Lee KY, Mooney DJ. Alginate: properties and biomedical applications. Prog Polym Sci. 2012;37:106–26.
24. Gåserød O, Smidsrød O, Skjåk-Bræk G. Microcapsules of alginate-chitosan—I: a quantitative study of the interaction between alginate and chitosan. Biomaterials. 1998;19:1815–25.
25. Sechriest VF, Miao YJ, Niyibizi C, Westerhausen-Larson A, Matthew HW, Evans CH, et al. GAG-augmented polysaccharide hydrogel: a novel biocompatible and biodegradable material to support chondrogenesis. J Biomed Mater Res. 2000;49:534–41.
26. Bhattarai N, Gunn J, Zhang M. Chitosan-based hydrogels for controlled, localized drug delivery. Adv Drug Deliv Rev. 2010;62:83–99.
27. Augst AD, Kong HJ, Mooney DJ. Alginate hydrogels as biomaterials. Macromol Biosci. 2006;6:623–33.
28. Sikorski P, Mo F, Skjåk-Bræk G, Stokke BT. Evidence for egg-box-compatible interactions in calcium-alginate gels from fiber X-ray diffraction. Biomacromolecules. 2007;8:2098–103.
29. Chan G, Mooney DJ. Ca2+ released from calcium alginate gels can promote inflammatory responses in vitro and in vivo. Acta Biomater. 2013;9:9281–91.
30. Orive G, Ponce S, Hernández RM, Gascón AR, Igartua M, Pedraz JL. Biocompatibility of microcapsules for cell immobilization elaborated with different type of alginates. Biomaterials. 2002;23:3825–31.
31. Soon-Shiong P, Otterlie M, Skjak-Braek G, Smidsrod O, Heintz R, Lanza RP, et al. An immunologic basis for the fibrotic reaction to implanted microcapsules. Transplant Proc. 1991;23:758–9.
32. Clayton HA, London NJ, Colloby PS, Bell PR, James RF. The effect of capsule composition on the biocompatibility of alginate-poly-1-lysine capsules. J Microencapsul. 1991;8:221–33.
33. Otterlei M, Østgaard K, Skjåk-Bræk G, Smidsrød O, Soon-Shiong P, Espevik T. Induction of cytokine production from human monocytes stimulated with alginate. J Immunother. 1991;10:286–91.
34. Zimmermann U, Klöck G, Federlin K, Hannig K, Kowalski M, Bretzel RG, et al. Production of mitogen‐contamination free alginates with variable ratios of mannuronic acid to guluronic acid by free flow electrophoresis. Electrophoresis. 1992;13:269–74.
35. Lee J, Lee KY. Local and sustained vascular endothelial growth factor delivery for angiogenesis using an injectable system. Pharm Res. 2009;26:1739–44.
36. Edwards DA, Hanes J, Caponetti G, Hrkach J, Ben-Jebria A, Eskew ML, et al. Large porous particles for pulmonary drug delivery. Science. 1997;276:1868–71.
37. Lin CE, Deng Jr Y, Liao WS, Sun SW, Lin WY, Chen CC. Electrophoretic behavior and pKa determination of quinolones with a piperazinyl substituent by capillary zone electrophoresis. J Chromatogr A. 2004;1051:283–90.
38. Smyth HD, Hickey AJ. Carriers in drug powder delivery. Am J Drug Deliv. 2005;3:117–32.
39. Sung JC, Padilla DJ, Garcia-Contreras L, Verberkmoes JL, Durbin D, Peloquin CA, et al. Formulation and pharmacokinetics of self-assembled rifampicin nanoparticle systems for pulmonary delivery. Pharm Res. 2009;26:1847–55.
40. Wang YB, Watts AB, Peters JI, Liu S, Batra A, Williams III RO. In vitro and in vivo performance of dry powder inhalation formulations: comparison of particles prepared by thin film freezing and micronization. AAPS PharmSciTech. 2014. doi:10.1208/s12249-014-0126-7.
41. Zhang J, Wu L, Chan HK, Watanabe W. Formation, characterization, and fate of inhaled drug nanoparticles. Adv Drug Deliv Rev. 2011;63:441–55.
42. Olsson B, Bondesson E, Borgstrom L, et al. Pulmonary drug metabolism, clearance, and absorption. In: Smyth HD, Hickey AJ, editors. Controlled pulmonary drug delivery. New York: Springer; 2011. p. 21–50. doi:10.1007/978-1-4419-9745-6.